O	0	5	Phase
O	6	8	II
O	8	9	,
O	10	20	randomized
O	20	21	,
O	22	28	double
O	28	29	-
O	29	34	blind
O	35	40	study
O	41	43	of
O	44	47	two
O	48	52	dose
O	53	59	levels
O	60	62	of
B-intervention	63	73	arzoxifene
O	74	76	in
O	77	85	patients
O	86	90	with
O	91	98	locally
O	99	107	advanced
O	108	110	or
O	111	121	metastatic
O	122	128	breast
O	129	135	cancer
O	135	136	.

O	137	139	To
O	140	146	select
O	147	148	a
O	149	154	daily
O	155	159	dose
O	160	162	of
O	163	173	arzoxifene
O	174	175	(
O	175	183	LY353381
O	183	184	)
O	184	185	,
O	186	187	a
O	188	197	selective
O	198	206	estrogen
O	207	215	receptor
O	216	225	modulator
O	225	226	,
O	227	230	for
O	231	234	use
O	235	237	in
O	238	244	future
O	245	252	studies
O	253	255	in
O	256	261	women
O	262	266	with
O	267	274	locally
O	275	283	advanced
O	284	286	or
O	287	297	metastatic
O	298	304	breast
O	305	311	cancer
O	312	315	who
O	316	319	are
O	320	326	either
O	327	338	potentially
O	339	348	tamoxifen
O	349	358	sensitive
O	359	360	(
O	360	362	TS
O	362	363	)
O	364	366	or
O	367	376	tamoxifen
O	377	387	refractory
O	388	389	(
O	389	391	TR
O	391	392	)
O	392	393	.

O	394	398	This
O	399	404	trial
O	405	408	was
O	409	410	a
O	411	421	randomized
O	421	422	,
O	423	429	double
O	429	430	-
O	430	435	blind
O	435	436	,
O	437	442	phase
O	443	445	II
O	446	451	study
O	452	454	of
O	455	465	arzoxifene
O	466	468	20
O	469	471	mg
O	472	473	(
O	473	474	n
O	475	476	=
B-intervention-participants	477	479	55
O	479	480	)
O	481	484	and
B-control	485	487	50
I-control	488	490	mg
O	491	492	(
O	492	493	n
O	494	495	=
B-control-participants	496	498	57
O	498	499	)
O	500	502	in
B-eligibility	503	508	women
I-eligibility	509	513	with
I-eligibility	514	522	advanced
I-eligibility	523	525	or
I-eligibility	526	536	metastatic
I-eligibility	537	543	breast
I-eligibility	544	550	cancer
O	550	551	.

O	552	560	Patients
O	561	565	were
O	566	574	randomly
O	575	583	assigned
O	584	586	to
O	587	594	balance
O	595	598	for
O	599	605	number
O	606	608	of
O	609	619	metastatic
O	620	627	disease
O	628	633	sites
O	633	634	,
O	635	640	prior
O	641	650	tamoxifen
O	651	658	therapy
O	658	659	,
O	660	663	and
O	664	672	estrogen
O	673	681	receptor
O	682	688	status
O	688	689	.

O	690	693	The
O	694	701	primary
O	702	705	end
O	706	711	point
O	712	715	was
B-outcome-Measure	716	721	tumor
I-outcome-Measure	722	730	response
I-outcome-Measure	731	735	rate
O	736	737	(
O	737	739	RR
O	739	740	)
O	740	741	.

O	742	751	Secondary
O	752	755	end
O	756	762	points
O	763	771	included
B-outcome-Measure	772	780	clinical
I-outcome-Measure	781	788	benefit
I-outcome-Measure	789	793	rate
I-outcome-Measure	794	795	(
I-outcome-Measure	795	798	CBR
I-outcome-Measure	798	799	)
O	799	800	,
B-outcome-Measure	801	805	time
I-outcome-Measure	806	808	to
I-outcome-Measure	809	820	progression
I-outcome-Measure	821	822	(
I-outcome-Measure	822	825	TTP
I-outcome-Measure	825	826	)
O	826	827	,
O	828	831	and
B-outcome-Measure	832	840	toxicity
O	840	841	.

B-total-participants	842	847	Forty
I-total-participants	847	848	-
I-total-participants	848	852	nine
O	853	861	patients
O	862	866	were
O	867	869	TS
O	870	873	and
B-total-participants	874	876	63
O	877	881	were
O	882	884	TR
O	884	885	.

O	886	895	According
O	896	898	to
O	899	910	independent
O	911	917	review
O	917	918	,
O	919	924	among
O	925	927	TS
O	928	936	patients
O	936	937	,
B-outcome	938	940	RR
O	941	944	was
O	945	951	higher
O	952	954	in
O	955	958	the
O	959	961	20
O	961	962	-
O	962	964	mg
O	965	968	arm
O	969	973	than
O	974	977	the
O	978	980	50
O	980	981	-
O	981	983	mg
O	984	987	arm
O	988	989	(
B-iv-bin-percent	989	991	26
I-iv-bin-percent	991	992	.
I-iv-bin-percent	992	993	1
I-iv-bin-percent	993	994	%
O	995	996	v
B-cv-bin-percent	997	998	8
I-cv-bin-percent	998	999	.
I-cv-bin-percent	999	1000	0
I-cv-bin-percent	1000	1001	%
O	1001	1002	)
O	1002	1003	,
O	1004	1008	with
O	1009	1010	a
O	1011	1017	longer
B-outcome	1018	1021	TTP
O	1022	1023	(
B-iv-cont-median	1023	1024	8
I-iv-cont-median	1024	1025	.
I-iv-cont-median	1025	1026	3
O	1027	1028	v
B-cv-cont-median	1029	1030	3
I-cv-cont-median	1030	1031	.
I-cv-cont-median	1031	1032	2
I-cv-cont-median	1033	1039	months
O	1039	1040	;
O	1041	1042	P
O	1043	1044	>
O	1044	1045	.
O	1045	1047	05
O	1047	1048	)
O	1048	1049	.

O	1050	1055	Among
O	1056	1059	the
O	1060	1062	TR
O	1063	1071	patients
O	1071	1072	,
B-outcome	1073	1081	response
I-outcome	1082	1086	rate
O	1087	1090	was
O	1091	1094	the
O	1095	1099	same
O	1100	1102	in
O	1103	1106	the
O	1107	1109	20
O	1109	1110	-
O	1110	1112	mg
O	1113	1116	and
O	1117	1119	50
O	1119	1120	-
O	1120	1122	mg
O	1123	1127	arms
O	1128	1129	(
B-iv-bin-percent	1129	1131	10
I-iv-bin-percent	1131	1132	.
I-iv-bin-percent	1132	1133	3
I-iv-bin-percent	1133	1134	%
O	1134	1135	)
O	1136	1140	with
O	1141	1148	similar
B-outcome	1149	1152	TTP
O	1153	1154	(
B-iv-cont-mean	1154	1155	2
I-iv-cont-mean	1155	1156	.
I-iv-cont-mean	1156	1157	7
O	1158	1161	and
B-cv-cont-mean	1162	1163	2
I-cv-cont-mean	1163	1164	.
I-cv-cont-mean	1164	1165	8
I-cv-cont-mean	1166	1172	months
O	1172	1173	,
O	1174	1186	respectively
O	1186	1187	;
O	1188	1189	P
O	1190	1191	>
O	1191	1192	.
O	1192	1194	05
O	1194	1195	)
O	1195	1196	.

B-outcome	1197	1200	CBR
O	1201	1204	was
O	1205	1211	higher
O	1212	1214	in
O	1215	1218	the
O	1219	1221	20
O	1221	1222	-
O	1222	1224	mg
O	1225	1228	arm
O	1229	1233	than
O	1234	1236	in
O	1237	1240	the
O	1241	1243	50
O	1243	1244	-
O	1244	1246	mg
O	1247	1250	arm
O	1251	1256	among
O	1257	1259	TS
O	1260	1268	patients
O	1269	1270	(
B-iv-bin-percent	1270	1272	39
I-iv-bin-percent	1272	1273	.
I-iv-bin-percent	1273	1274	1
I-iv-bin-percent	1274	1275	%
O	1276	1277	v
B-cv-bin-percent	1278	1280	20
I-cv-bin-percent	1280	1281	.
I-cv-bin-percent	1281	1282	0
I-cv-bin-percent	1282	1283	%
O	1283	1284	)
O	1285	1288	and
B-outcome	1289	1291	TR
I-outcome	1292	1300	patients
O	1301	1302	(
B-iv-bin-percent	1302	1304	13
I-iv-bin-percent	1304	1305	.
I-iv-bin-percent	1305	1306	8
I-iv-bin-percent	1306	1307	%
O	1308	1309	v
B-cv-bin-percent	1310	1312	10
I-cv-bin-percent	1312	1313	.
I-cv-bin-percent	1313	1314	3
I-cv-bin-percent	1314	1315	%
O	1315	1316	)
O	1316	1317	.

O	1318	1328	Arzoxifene
O	1329	1332	was
O	1333	1337	well
O	1338	1347	tolerated
O	1347	1348	.

B-outcome	1349	1353	Dose
I-outcome	1353	1354	-
I-outcome	1354	1363	dependent
I-outcome	1364	1372	toxicity
O	1373	1376	was
O	1377	1380	not
O	1381	1393	demonstrated
O	1393	1394	.

O	1395	1400	There
O	1401	1405	were
B-outcome	1406	1408	no
I-outcome	1409	1415	deaths
O	1416	1422	during
O	1423	1428	study
O	1428	1429	.

O	1430	1440	Arzoxifene
O	1441	1443	is
O	1444	1453	effective
O	1454	1456	in
O	1457	1460	the
O	1461	1470	treatment
O	1471	1473	of
O	1474	1476	TS
O	1477	1480	and
O	1481	1483	TR
O	1484	1492	patients
O	1493	1497	with
O	1498	1506	advanced
O	1507	1509	or
O	1510	1520	metastatic
O	1521	1527	breast
O	1528	1534	cancer
O	1535	1537	at
O	1538	1541	the
O	1542	1544	20
O	1544	1545	-
O	1545	1547	mg
O	1548	1551	and
O	1552	1554	50
O	1554	1555	-
O	1555	1557	mg
O	1558	1562	dose
O	1563	1569	levels
O	1569	1570	.

B-outcome	1571	1581	Toxicities
O	1582	1585	are
O	1586	1593	minimal
O	1593	1594	,
O	1595	1598	and
O	1599	1602	the
O	1603	1610	therapy
O	1611	1613	is
O	1614	1623	tolerated
O	1623	1624	.

O	1625	1628	The
O	1629	1631	20
O	1631	1632	-
O	1632	1634	mg
O	1635	1639	dose
O	1640	1645	seems
O	1646	1648	to
O	1649	1651	be
O	1652	1654	at
O	1655	1660	least
O	1661	1663	as
O	1664	1673	effective
O	1674	1676	as
O	1677	1680	the
O	1681	1683	50
O	1683	1684	-
O	1684	1686	mg
O	1687	1691	dose
O	1691	1692	.

O	1693	1704	Accordingly
O	1704	1705	,
O	1706	1716	arzoxifene
O	1717	1719	20
O	1720	1722	mg
O	1722	1723	/
O	1723	1724	d
O	1725	1728	was
O	1729	1737	selected
O	1738	1741	for
O	1742	1749	further
O	1750	1755	study
O	1756	1758	in
O	1759	1767	patients
O	1768	1772	with
O	1773	1779	breast
O	1780	1786	cancer
O	1786	1787	.
